Pfizer beats Q2 profit estimates on Eliquis strength; raises full-year revenue guidance

GPN -0.47% CPRI +1.24%

1. 1Pfizer's Q2 profit exceeded Wall Street estimates on strong demand for blood thinner Eliquis
2. 2Adjusted EPS came in at $0.77 vs. $0.78 estimate; full-year revenue guidance raised to $60.5B–$62.5B
3. 3Offsetting COVID revenue declines with new drugs, with growth recovery expected after 2028

Source Reuters +2 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →